期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma:A case report
1
作者 Yu Igata Masashi Kudo +8 位作者 Motohiro Kojima Shota Kami Keishiro Aoki Tomoyuki Satake Tatsushi Kobayashi Motokazu Sugimoto Shin Kobayashi Masaru Konishi naoto gotohda 《World Journal of Clinical Cases》 SCIE 2024年第34期6721-6727,共7页
BACKGROUND The combination of immune checkpoint inhibitors and chemotherapy has shown promising results for the treatment of advanced biliary tract cancer(BTC).Based on the results of the TOPAZ-1 trial,a gemcitabine a... BACKGROUND The combination of immune checkpoint inhibitors and chemotherapy has shown promising results for the treatment of advanced biliary tract cancer(BTC).Based on the results of the TOPAZ-1 trial,a gemcitabine and cisplatin plus durvalumab(GCD)regimen was recently approved as first-line therapy for patients with advanced BTC.However,post-GCD conversion surgery has not been previously studied.Herein,we describe a case of advanced intrahepatic cholangiocarcinoma(ICC)successfully treated with radical surgery after GCD.CASE SUMMARY A 65-year-old female diagnosed with advanced ICC with periductal infiltration into the hepatic hilum underwent eight cycles of GCD,followed by durvalumab maintenance treatment,with mild adverse events.Partial response was obtained.Subsequently,a conversion surgery with extended left hepatectomy and bile duct resection was performed.The resection margins were negative,and the pathological diagnosis was compatible with small duct type ICC.The patient remained disease-free for 8 months without adjuvant chemotherapy.CONCLUSION We describe the case of a patient who received successful conversion surgery after GCD treatment for advanced ICC. 展开更多
关键词 Conversion surgery Intrahepatic cholangiocarcinoma Small duct type Immunotherapy Case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部